

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2022/017633 A8

(43) International Publication Date
27 January 2022 (27.01.2022)

(51) International Patent Classification:

C12N 9/22 (2006.01) C12N 15/82 (2006.01)
C12N 15/10 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/000081

(22) International Filing Date:

20 July 2021 (20.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20000262.4 21 July 2020 (21.07.2020) EP
20000329.1 10 September 2020 (10.09.2020) EP

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

10 March 2022 (10.03.2022)

(48) Date of publication of this corrected version:

07 April 2022 (07.04.2022)

(15) Information about Correction:

see Notice of 07 April 2022 (07.04.2022)

(71) Applicant: **BRAIN BIOTECH AG** [DE/DE]; Darmstädter
Straße 34-36, 64673 Zwingenberg (DE).

(72) Inventors: **SCHOLZ, Paul**; Aachener Straße 236, 50931
Köln (DE). **ZUREK, Christian**; Thymianplatz 1, 64653
Lorsch (DE). **KROHN, Michael**; Alexanderstraße 8, 64653
Lorsch (DE).

(74) Agent: **HEUBECK, Christian**; Weickmann & Weick-
mann PartmbB, Richard-Strauss-Str. 80, 81679 Munich
(DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: NOVEL, NON-NATURALLY OCCURRING CRISPR-CAS NUCLEASES FOR GENOME EDITING

(57) Abstract: The present invention relates to a nucleic acid molecule encoding an RNA-guided DNA endonuclease, which is (a) a nucleic acid molecule encoding the RNA-guided DNA endonuclease comprising or consisting of the amino acid sequence of SEQ ID NO: 29, 1 or 3; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 30, 2 or 4; (c) a nucleic acid molecule encoding a RNA-guided DNA endonuclease the amino acid sequence of which is at least 90 %, preferably at least 92 %, and most preferably at least 95 % identical to the amino acid sequence of (a); (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 90 %, preferably at least 92 %, and most preferably at least 95 % identical to the nucleotide sequence of (b); (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.



WO 2022/017633 A8